| HIV Infections
Biktarvy vs Dovato
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Biktarvy vs Dovato with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDovato has a higher rate of injection site reactions vs Biktarvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dovato but not Biktarvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Biktarvy
Dovato
At A Glance
Oral
Daily
INSTI + NRTI combination
Oral
Once daily
INSTI/NRTI combination
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections - adults and pediatric >= 25 kg One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; on hemodialysis days, administer after hemodialysis completion.
HIV Infections - pediatric 14 kg to < 25 kg One tablet (30 mg BIC/120 mg FTC/15 mg TAF) taken orally once daily with or without food.
HIV Infections - virologically-suppressed pregnant individuals One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; monitor viral load closely due to lower drug exposures during pregnancy.
HIV Infections One tablet (dolutegravir 50 mg/lamivudine 300 mg) orally once daily with or without food; when coadministered with carbamazepine or rifampin, take one additional dolutegravir 50-mg tablet approximately 12 hours after the DOVATO dose.
Contraindications
- Co-administration with dofetilide due to potential for increased dofetilide plasma concentrations and serious or life-threatening events
- Co-administration with rifampin due to substantially decreased BIC plasma concentrations, which may result in loss of therapeutic effect and development of resistance
- Prior hypersensitivity reaction to dolutegravir or lamivudine
- Concurrent use of dofetilide due to risk of increased dofetilide plasma concentrations and serious or life-threatening events
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, headache
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, angioedema, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria, weight increased
Most common (>=2%) Headache, nausea, diarrhea, insomnia, fatigue, anxiety, dizziness
Serious Hypersensitivity reactions, hepatotoxicity, lactic acidosis and severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Body fat redistribution, hyperglycemia, weakness, severe anemia, lactic acidosis and hepatic steatosis, pancreatitis, posttreatment exacerbations of HBV, acute liver failure, anaphylaxis, urticaria, weight gain, arthralgia, CPK elevation, muscle weakness, myalgia, rhabdomyolysis, paresthesia, peripheral neuropathy, alopecia
Pharmacology
BIKTARVY is a fixed-dose combination antiretroviral containing bictegravir (BIC), an integrase strand transfer inhibitor (INSTI) that blocks integration of HIV-1 DNA into host genomic DNA, plus emtricitabine (FTC) and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors (NRTIs) that terminate viral DNA chain elongation by competing with natural nucleoside substrates.
DOVATO is a fixed-dose combination of dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks retroviral DNA integration by binding to the integrase active site, and lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Biktarvy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Dovato
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Biktarvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Dovato
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Biktarvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Dovato
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BiktarvyView full Biktarvy profile
DovatoView full Dovato profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.